Millennium Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Millennium Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#207 of 15,742 sponsors by registered trial count).
Millennium Pharmaceuticals: 135 sponsored US clinical trials, none currently recruiting.
Millennium Pharmaceuticals sponsors 135 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 119 completed. 17 of these trials are in Phase 3-4 (later-stage) and 117 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lymphoma, with 3 trials.
Top-decile sponsor footprint
Millennium Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#207 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
119 of 135 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
135 total, page 2 of 3
Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas
NCT01898078
A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies
NCT01899053
Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
NCT01844583
Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors
NCT01862328
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
NCT01850524
Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older
NCT01814826
Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib
NCT01714947
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
NCT01659658
Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer
NCT01666314
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
NCT01482962
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
NCT01578499
Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C
NCT01577758
Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT01549951
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
NCT01492088
Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma
NCT01454076
Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma
NCT01383928
Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer
NCT01449370
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
NCT01425008
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine
NCT01397825
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
NCT01335685
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
NCT01318902
Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
NCT01351350
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
NCT01217957
Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.
NCT01193257
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
NCT01224171
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
NCT01118689
Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
NCT01193244
A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies
NCT01204073
Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies
NCT01179399
A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
NCT01094288
Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
NCT01084655
Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen
NCT01046916
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
NCT01091428
Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
NCT01045421
Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies
NCT01058707
Dose Escalation Study of MLN4924 in Adults With Melanoma
NCT01011530
Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
NCT00948467
Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
NCT00932698
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
NCT00931918
Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma
NCT00963820
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
NCT00935844
Study of MLN8237 in Participants With Advanced Solid Tumors
NCT00962091
A Study of IXAZOMIB in Adult Patients With Lymphoma
NCT00893464
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
NCT00911066
MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma
NCT00853307
A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies
NCT00830869
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
NCT00807677
Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies
NCT00831896
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
NCT00807495
A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
NCT00830518
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 86 |
| Phase 2 | 31 |
| Phase 3 | 16 |
| Phase 4 | 1 |
Therapeutic Areas
How the Millennium Pharmaceuticals early-phase archive is shaped
135 indexed studies, none listed as recruiting (0% open); 119 completed (88%).
Phase mix: 17 late (III/IV) vs 117 early (I/II) (early-phase heavy).
Top condition: Lymphoma (3 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Millennium Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 135 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Millennium Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 135 archived trials
- The Miriam Hospital · 136 trials · 11% recruiting
- George Washington University · 133 trials · 18% recruiting
- Shirley Ryan AbilityLab · 138 trials · 26% recruiting
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · 138 trials · 3% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Millennium Pharmaceuticals page
135 registered trials is a research-attention snapshot, not an endorsement of Millennium Pharmaceuticals or any single study.
- None of Millennium Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Lymphoma is the condition Millennium Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Millennium Pharmaceuticals pipeline card: 135 registered trials from official public datasets.Report a data error.